Back to search results
NCT06464315

Functional Substrate-Only Guided VT Ablation

Enrolling by Invitation
NAAges 18–90InterventionalTreatment
VA Office of Research and Development
~36 participants
Updated 2026-03-25 on ClinicalTrials.gov
What's tested:Functional Substrate-Only Mapping without VT InductionStandard-of-Care Mapping/Imaging

At a glance

Recruiting sites
0 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Time to composite endpoint (VT recurrence, death, or acute hemodynamic decompensation)
Measured over 6 months

Conditions

Ventricular Tachycardia
Sudden Cardiac Death

Explore related trials

Structural Heart DiseaseSudden Cardiac DeathVentricular Tachycardia

NCT06464315

Where you'd take part

This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • VA San Diego Healthcare System, San Diego, CA

    San Diego, Californiano site contact published

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Study leadership

  • Gordon Ho, MD · PRINCIPAL_INVESTIGATOR · VA San Diego Healthcare System, San Diego, CA

Who to contact

This trial hasn't published a contact. View it on ClinicalTrials.gov

Want this trial checked against your situation?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Men and women \>18 years of age referred for clinically indicated VT ablation and experience monomorphic or polymorphic scar-based VT documented by telemetry, ICD interrogation, ECG or event monitoring.
Scar-based VT is defined as VT in patients with structural heart disease (assessed with either abnormal nuclear perfusion imaging (\>5% defect), late gadolinium uptake on cardiac MRI, wall thinning \<10mm or calcified myocardium on cardiac CT, akinesis or hypokinesis on echocardiogram, presence of Q waves on ECG, history of myocardial infarct).
Patients undergoing epicardial VT ablation and who undergo prophylactic percutaneous hemodynamic support devices will also be included.

Exclusion

Patients without structural heart disease will be excluded from the pri-mary analysis, but enrolled in a prospective registry
Patients who are pregnant
Presence of intracardiac thrombus
active acute coronary ischemia with unrevascularized coronary artery disease (CAD \>70% stenosis)
Active bacteremia
Inaccessible ventricles due to dual mechanical valves
Inability to tolerate and inability to tolerate anticoagulation during ablation and for at least 1 month after ablation

What this trial measures

  • Time to composite endpoint (VT recurrence, death, or acute hemodynamic decompensation)6 months

    Ventricular arrhythmia recurrence is defined by an episode of sustained VT lasting 30 seconds or appropriate implantable cardioverter-defibrillator therapy including anti-tachycardia pacing or shock. Acute hemodynamic decompensation is defined by escalation of at least 1 new high dose inotrope/pressor occurring after anesthesia induction with persistent requirement during stable rhythm, \>20% drop in cardiac index, unplanned insertion of percutaneous hemodynamic support device.